Inclacumab, a P-selectin inhibitor, was used in a randomised trial of 544 NSTEMI patients, but the inconclusive results only showed a trend towards a reduction in troponin levels in the treatment arm [ 34 ].
← all excerpts
The Role of Extracellular DNA and Histones in Ischaemia-Reperfusion Injury of the Myocardium.
1
—
—